Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;11(5):378-85.
doi: 10.1007/s11912-009-0051-1.

The future of small molecule inhibitors in lymphoma

Affiliations
Review

The future of small molecule inhibitors in lymphoma

John Gerecitano. Curr Oncol Rep. 2009 Sep.

Abstract

For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6 - PubMed
    1. Blood. 2008 Feb 15;111(4):2230-7 - PubMed
    1. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7 - PubMed
    1. Clin Cancer Res. 2006 Sep 1;12(17):5165-73 - PubMed
    1. Curr Opin Oncol. 2003 Nov;15(6):419-24 - PubMed

MeSH terms

LinkOut - more resources